近日,武田制药公司开发的Colcrys作为首个单一成分的秋水仙碱产品用于治疗痛风。该药还获准用于一种遗传性周期性发热综合征—家族性地中海热(FMF),成为首个获准用于该疾病的药物。目前仅有含秋水仙碱和丙磺舒的复方产品获准用于痛风治疗。
用法用量
痛风发作：
预防痛风发作：0.6毫克每天一次或在成人和年龄超过16岁青少年的两倍。最大剂量1.2毫克/天。
治疗痛风：1.2毫克（2片）在痛风发作其次是0.6毫克（1片），一小时后的第一个迹象。
FMF：成人及12岁以上儿童1.2-2.4毫克;儿童6至12岁0.9-1.8毫克;儿童4〜6年0.3 -1.8毫克。
给予每日总剂量在一个或两个分开的剂量。
增加或减少剂量所示，并作为耐受性为0.3mg/天的增量，但不超过最大推荐每日剂量。
秋水仙碱片剂口服给药时，没有考虑到食物。
调整剂量有关患者肾功能受损，肝功能受损完整的处方信息，患者的年龄，或使用共施用的药物。
剂型和规格
0.6毫克的片剂。
公司名称：
武田制药北美公司
Colcrys (Generic Colchicine) 0.6mg
The generic version of Colchicine 0.6mg contains the same active ingredients as the original brand name drug, and is as just as effective. CanadaDrugsOnline.com provides generic Colchicine tablets which meet the quality and safety standards to ensure your health. Generic Colchicine is made by Odan or Jamp Pharma in Canada. Colchicine belongs to a class of medications called anti-gout or anti-inflammatory drugs, and is used to treat:
• Acute attacks of gout (also called gouty arthritis)
• Familial Mediterranean fever (FMF)
• Symptoms of Behcets syndrome such as pain, redness, and swelling
Colchicine Generic Dosage
Colchicine tablets should be taken as directed on the package and by your doctor. Colchicine generic is available in various doses, including 0.5 mg, 0.6 mg, and 1.0 mg. You should store Colchicine in a cool dry place away from direct sunlight. Only use Colchicine as directed by your doctor, and never exceed the stated dose.
COLCRYS Rx
Generic Name and Formulations:
Colchicine 0.6mg; tabs.
Company:
Takeda Pharmaceuticals North America, Inc.
Indications for COLCRYS:
Prophylaxis and treatment of acute gout flares. Familial Mediterranean fever (FMF).
Adult:
Gout prophylaxis: >16yrs: 0.6mg once or twice daily; max 1.2mg/day. Gout treatment: 1.2mg at first sign of gout flare, then 0.6mg 1 hour later; max 1.8mg over a 1 hour period; may be given during prophylaxis at max 1.2mg at first sign of flare, then 0.6mg 1 hour later, wait 12 hours, then resume prophylactic dose. FMF: Usual range: 1.2mg–2.4mg daily; may give in 1–2 divided doses. May increase/decrease dose (depending on tolerability) in increments of 0.3mg/day to max daily dose. For all: concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).
Children:
FMF: <4yrs: not recommended. Give as a single or divided dose twice daily. 4–6yrs: 0.3mg–1.8mg daily; 6–12yrs: 0.9mg–1.8mg daily. May increase/decrease dose (depending on tolerability) in increments of 0.3mg/day to max daily dose. Concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).
Contraindications:
Renal or hepatic impairment with concomitant strong CYP3A4 or P-glycoprotein inhibitors (life-threatening toxicity possible).
Warnings/Precautions:
Monitor for toxicity; if present, consider temporary interruption or discontinuation. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Interactions:
See Contraindications. Potentiated by concomitant CYP3A4 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, grapefruit juice) and/or P-glycoprotein inhibitors (eg, cyclosporine, ranolazine). Concomitant statins, gemfibrozil, fibrates, digoxin may potentiate myopathy and rhabdomyolysis.
Pharmacological Class:
Antiinflammatory (alkaloid).
Adverse Reactions:
GI upset, abdominal pain, pharyngolaryngeal pain; blood dyscrasias (myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia), neuromuscular toxicity, rhabdomyolysis, overdosage (may be fatal).
Generic Availability:
YES
How Supplied:
Tabs—30, 60, 100, 250, 500, 1000
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7